You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameAtomoxetine
Accession NumberDB00289  (APRD00614)
TypeSmall Molecule
GroupsApproved
Description

Atomoxetine is the first non-stimulant drug approved for the treatment of attention-deficit hyperactivity disorder (ADHD). It is sold in the form of the hydrochloride salt of atomoxetine. This chemical is manufactured and marketed under the brand name Strattera; by Eli Lilly and Company and as a generic Attentin by Torrent Pharmaceuticals. There is currently no generic available within the United States due to patent restrictions. [Wikipedia]

Structure
Thumb
Synonyms
(-)-Tomoxetine
Tomoxetina
Tomoxetine
Tomoxetinum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Atomoxetinecapsule60 mgoralSivem Pharmaceuticals Ulc2015-10-07Not applicableCanada
Atomoxetinecapsule40 mgoralSivem Pharmaceuticals Ulc2015-10-07Not applicableCanada
Atomoxetinecapsule25 mgoralSivem Pharmaceuticals Ulc2015-10-07Not applicableCanada
Atomoxetinecapsule18 mgoralSivem Pharmaceuticals Ulc2015-10-07Not applicableCanada
Atomoxetinecapsule60 mgoralPro Doc Limitee2012-11-29Not applicableCanada
Atomoxetinecapsule10 mgoralSivem Pharmaceuticals Ulc2015-10-07Not applicableCanada
Atomoxetinecapsule40 mgoralPro Doc Limitee2012-11-29Not applicableCanada
Atomoxetinecapsule25 mgoralPro Doc Limitee2012-11-29Not applicableCanada
Atomoxetinecapsule18 mgoralPro Doc Limitee2012-11-29Not applicableCanada
Atomoxetinecapsule10 mgoralPro Doc Limitee2012-11-29Not applicableCanada
Dom-atomoxetinecapsule60 mgoralDominion Pharmacal2013-05-22Not applicableCanada
Dom-atomoxetinecapsule40 mgoralDominion Pharmacal2013-04-23Not applicableCanada
Dom-atomoxetinecapsule25 mgoralDominion Pharmacal2013-04-23Not applicableCanada
Dom-atomoxetinecapsule18 mgoralDominion PharmacalNot applicableNot applicableCanada
Dom-atomoxetinecapsule10 mgoralDominion PharmacalNot applicableNot applicableCanada
Mylan-atomoxetinecapsule60 mgoralMylan Pharmaceuticals Ulc2012-01-31Not applicableCanada
Mylan-atomoxetinecapsule40 mgoralMylan Pharmaceuticals Ulc2012-01-31Not applicableCanada
Mylan-atomoxetinecapsule25 mgoralMylan Pharmaceuticals Ulc2012-01-31Not applicableCanada
Mylan-atomoxetinecapsule18 mgoralMylan Pharmaceuticals Ulc2012-01-31Not applicableCanada
Mylan-atomoxetinecapsule100 mgoralMylan Pharmaceuticals Ulc2012-01-31Not applicableCanada
Mylan-atomoxetinecapsule80 mgoralMylan Pharmaceuticals Ulc2012-01-31Not applicableCanada
PMS-atomoxetinecapsule60 mgoralPharmascience Inc2012-06-13Not applicableCanada
PMS-atomoxetinecapsule40 mgoralPharmascience Inc2012-06-13Not applicableCanada
PMS-atomoxetinecapsule100 mgoralPharmascience IncNot applicableNot applicableCanada
PMS-atomoxetinecapsule25 mgoralPharmascience Inc2012-06-13Not applicableCanada
PMS-atomoxetinecapsule80 mgoralPharmascience IncNot applicableNot applicableCanada
PMS-atomoxetinecapsule18 mgoralPharmascience Inc2012-06-13Not applicableCanada
PMS-atomoxetinecapsule10 mgoralPharmascience Inc2012-06-13Not applicableCanada
Ratio-atomoxetinecapsule10 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ratio-atomoxetinecapsule60 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ratio-atomoxetinecapsule40 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ratio-atomoxetinecapsule25 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Ratio-atomoxetinecapsule18 mgoralTeva Canada LimitedNot applicableNot applicableCanada
Riva-atomoxetinecapsule40 mgoralLaboratoire Riva Inc2013-07-19Not applicableCanada
Riva-atomoxetinecapsule25 mgoralLaboratoire Riva Inc2013-07-19Not applicableCanada
Riva-atomoxetinecapsule18 mgoralLaboratoire Riva Inc2013-07-19Not applicableCanada
Riva-atomoxetinecapsule100 mgoralLaboratoire Riva IncNot applicableNot applicableCanada
Riva-atomoxetinecapsule10 mgoralLaboratoire Riva Inc2013-07-18Not applicableCanada
Riva-atomoxetinecapsule80 mgoralLaboratoire Riva IncNot applicableNot applicableCanada
Riva-atomoxetinecapsule60 mgoralLaboratoire Riva Inc2013-07-19Not applicableCanada
Sandoz Atomoxetinecapsule10 mgoralSandoz Canada Incorporated2012-05-30Not applicableCanada
Sandoz Atomoxetinecapsule18 mgoralSandoz Canada Incorporated2012-05-30Not applicableCanada
Sandoz Atomoxetinecapsule100 mgoralSandoz Canada Incorporated2012-05-30Not applicableCanada
Sandoz Atomoxetinecapsule80 mgoralSandoz Canada Incorporated2012-05-30Not applicableCanada
Sandoz Atomoxetinecapsule60 mgoralSandoz Canada Incorporated2012-05-30Not applicableCanada
Sandoz Atomoxetinecapsule40 mgoralSandoz Canada Incorporated2012-05-30Not applicableCanada
Sandoz Atomoxetinecapsule25 mgoralSandoz Canada Incorporated2012-05-30Not applicableCanada
Stratteracapsule25 mg/1oralTYA Pharmaceuticals2003-01-10Not applicableUs
StratterakitoralEli Lilly and Company2014-08-31Not applicableUs
Stratteracapsule10 mg/1oralEli Lilly and Company2003-01-10Not applicableUs
Stratteracapsule10 mgoralEli Lilly Canada Inc2005-02-24Not applicableCanada
Stratteracapsule10 mg/1oralCarilion Materials Management2003-01-10Not applicableUs
StratterakitoralEli Lilly and Company2014-08-31Not applicableUs
Stratteracapsule40 mg/1oralAvera Mc Kennan Hospital2015-03-23Not applicableUs
Stratteracapsule40 mg/1oralCardinal Health2003-01-10Not applicableUs
Stratteracapsule100 mgoralEli Lilly Canada Inc2010-01-08Not applicableCanada
Stratteracapsule25 mg/1oralAvera Mc Kennan Hospital2015-03-05Not applicableUs
Stratteracapsule25 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-07-13Not applicableUs
Stratteracapsule100 mg/1oralEli Lilly and Company2006-03-01Not applicableUs
Stratteracapsule80 mgoralEli Lilly Canada Inc2009-12-16Not applicableCanada
Stratteracapsule10 mg/1oralAvera Mc Kennan Hospital2015-03-02Not applicableUs
Stratteracapsule80 mg/1oralREMEDYREPACK INC.2013-05-14Not applicableUs
Stratteracapsule80 mg/1oralEli Lilly and Company2006-03-01Not applicableUs
Stratteracapsule60 mgoralEli Lilly Canada Inc2005-03-03Not applicableCanada
Stratteracapsule60 mg/1oralCarilion Materials Management2003-01-10Not applicableUs
Stratteracapsule18 mg/1oralLake Erie Medical DBA Quality Care Products LLC2010-07-13Not applicableUs
Stratteracapsule60 mg/1oralEli Lilly and Company2003-01-10Not applicableUs
Stratteracapsule40 mg/1oralREMEDYREPACK INC.2013-05-09Not applicableUs
Stratteracapsule18 mg/1oralEli Lilly and Company2003-01-10Not applicableUs
Stratteracapsule40 mgoralEli Lilly Canada Inc2005-03-03Not applicableCanada
Stratteracapsule40 mg/1oralCarilion Materials Management2003-01-10Not applicableUs
Stratteracapsule10 mg/1oralSTAT Rx USA LLC2009-03-16Not applicableUs
Stratteracapsule40 mg/1oralEli Lilly and Company2003-01-10Not applicableUs
Stratteracapsule25 mgoralEli Lilly Canada Inc2005-03-03Not applicableCanada
Stratteracapsule25 mg/1oralCarilion Materials Management2003-01-10Not applicableUs
StratterakitoralEli Lilly and Company2014-08-31Not applicableUs
Stratteracapsule25 mg/1oralEli Lilly and Company2003-01-10Not applicableUs
Stratteracapsule18 mgoralEli Lilly Canada Inc2005-02-24Not applicableCanada
Stratteracapsule18 mg/1oralCarilion Materials Management2003-01-10Not applicableUs
Teva-atomoxetinecapsule25 mgoralTeva Canada Limited2010-09-16Not applicableCanada
Teva-atomoxetinecapsule18 mgoralTeva Canada Limited2010-09-16Not applicableCanada
Teva-atomoxetinecapsule10 mgoralTeva Canada Limited2010-09-16Not applicableCanada
Teva-atomoxetinecapsule100 mgoralTeva Canada Limited2013-10-15Not applicableCanada
Teva-atomoxetinecapsule80 mgoralTeva Canada Limited2014-02-28Not applicableCanada
Teva-atomoxetinecapsule60 mgoralTeva Canada Limited2010-09-16Not applicableCanada
Teva-atomoxetinecapsule40 mgoralTeva Canada Limited2010-09-16Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-atomoxetinecapsule40 mgoralApotex Inc2011-07-19Not applicableCanada
Apo-atomoxetinecapsule25 mgoralApotex Inc2011-03-15Not applicableCanada
Apo-atomoxetinecapsule18 mgoralApotex Inc2011-03-15Not applicableCanada
Apo-atomoxetinecapsule10 mgoralApotex Inc2011-03-15Not applicableCanada
Apo-atomoxetinecapsule100 mgoralApotex Inc2011-07-19Not applicableCanada
Apo-atomoxetinecapsule80 mgoralApotex Inc2011-07-19Not applicableCanada
Apo-atomoxetinecapsule60 mgoralApotex Inc2011-07-19Not applicableCanada
Atomoxetine Hydrochloridecapsule18 mg/1oralSun Pharma Global FZE2010-10-05Not applicableUs
Atomoxetine Hydrochloridecapsule10 mg/1oralSandoz Inc2010-12-15Not applicableUs
Atomoxetine Hydrochloridecapsule10 mg/1oralSun Pharma Global FZE2010-10-05Not applicableUs
Atomoxetine Hydrochloridecapsule100 mg/1oralSandoz Inc2010-12-15Not applicableUs
Atomoxetine Hydrochloridecapsule100 mg/1oralSun Pharma Global FZE2010-10-05Not applicableUs
Atomoxetine Hydrochloridecapsule80 mg/1oralSandoz Inc2010-12-15Not applicableUs
Atomoxetine Hydrochloridecapsule80 mg/1oralSun Pharma Global FZE2010-10-05Not applicableUs
Atomoxetine Hydrochloridecapsule60 mg/1oralSandoz Inc2010-12-15Not applicableUs
Atomoxetine Hydrochloridecapsule60 mg/1oralSun Pharma Global FZE2010-10-05Not applicableUs
Atomoxetine Hydrochloridecapsule40 mg/1oralSandoz Inc2010-12-15Not applicableUs
Atomoxetine Hydrochloridecapsule40 mg/1oralSun Pharma Global FZE2010-10-05Not applicableUs
Atomoxetine Hydrochloridecapsule25 mg/1oralSandoz Inc2010-12-15Not applicableUs
Atomoxetine Hydrochloridecapsule25 mg/1oralSun Pharma Global FZE2010-10-05Not applicableUs
Atomoxetine Hydrochloridecapsule18 mg/1oralSandoz Inc2010-12-15Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AttentinNot Available
TomoxetinNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Atomoxetine hydrochloride
82248-59-7
Thumb
  • InChI Key: LUCXVPAZUDVVBT-UNTBIKODSA-N
  • Monoisotopic Mass: 291.138992
  • Average Mass: 291.82
DBSALT001207
Categories
UNIIASW034S0B8
CAS number83015-26-3
WeightAverage: 255.3547
Monoisotopic: 255.162314299
Chemical FormulaC17H21NO
InChI KeyInChIKey=VHGCDTVCOLNTBX-QGZVFWFLSA-N
InChI
InChI=1S/C17H21NO/c1-14-8-6-7-11-16(14)19-17(12-13-18-2)15-9-4-3-5-10-15/h3-11,17-18H,12-13H2,1-2H3/t17-/m1/s1
IUPAC Name
methyl[(3R)-3-(2-methylphenoxy)-3-phenylpropyl]amine
SMILES
CNCC[C@@H](OC1=CC=CC=C1C)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpropylamines. These are compounds containing a phenylpropylamine moiety, which consists of a phenyl group substituted at the third carbon by an propan-1-amine.
KingdomOrganic compounds
Super ClassBenzenoids
ClassBenzene and substituted derivatives
Sub ClassPhenylpropylamines
Direct ParentPhenylpropylamines
Alternative Parents
Substituents
  • Phenylpropylamine
  • Phenol ether
  • Aralkylamine
  • Toluene
  • Alkyl aryl ether
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Amine
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) alone or in combination with behavioral treatment, as an adjunct to psychological, educational, social, and other remedial measures.
PharmacodynamicsAtomoxetine is the first non-stimulant drug approved for the treatment of attention-deficit hyperactivity disorder (ADHD). Atomoxetine is classified as a norepinephrine reuptake inhibitor, and is approved for use in children, adolescents, and adults. However, its efficacy has not been studied in children under six years old. Its advantage over stimulants for the treatment of ADHD is that it has less abuse potential than stimulants, is not scheduled as a controlled substance and has proven in clinical trials to offer 24 hour coverage of symptoms associated with ADHD in adults and children.
Mechanism of actionThe precise mechanism by which atomoxetine produces its therapeutic effects in Attention-Deficit/Hyperactivity Disorder (ADHD) is unknown, but is thought to be related to selective inhibition of the pre-synaptic norepinephrine transporter, as determined through in-vitro studies. Atomoxetine appears to have minimal affinity for other noradrenergic receptors or for other neurotransmitter transporters or receptors.
Related Articles
AbsorptionAtomoxetine is rapidly absorbed after oral administration, with absolute bioavailability of about 63% in EMs and 94% in PMs. Drugs that elevate gastric pH (magnesium hydroxide/aluminum hydroxide, omeprazole) have no effect on atomoxetine bioavailability. Absorption is minimally affected by food.
Volume of distribution
  • 0.85 L/kg
Protein bindingAt therapeutic concentrations, 98% of atomoxetine in plasma is bound to protein, primarily albumin.
Metabolism

Atomoxetine is primarily metabolized by the CYP2D6 pathway to 4-hydroxyatomoxetine. 4-Hydroxyatomoxetine is equipotent to atomoxetine as an inhibitor of the norepinephrine transporter but circulates in plasma at much lower concentrations (1% of atomoxetine concentration in EMs and 0.1% of atomoxetine concentration in PMs).

SubstrateEnzymesProduct
Atomoxetine
Not Available
4-hydroxyatomoxetineDetails
Route of eliminationNot Available
Half life5 hours
Clearance
  • 0.35 L/hr/kg [after oral administration in adult extensive metabolizers]
  • 0.03 L/hr/kg [administration of atomoxetine to poor metabolizers]
ToxicityThe most commonly reported symptoms accompanying acute and chronic overdoses are somnolence, agitation, hyperactivity, abnormal behavior, and gastrointestinal symptoms.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.964
Caco-2 permeable+0.852
P-glycoprotein substrateSubstrate0.6133
P-glycoprotein inhibitor IInhibitor0.7771
P-glycoprotein inhibitor IINon-inhibitor0.8003
Renal organic cation transporterInhibitor0.5929
CYP450 2C9 substrateNon-substrate0.7443
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.6216
CYP450 1A2 substrateInhibitor0.9324
CYP450 2C9 inhibitorNon-inhibitor0.957
CYP450 2D6 inhibitorInhibitor0.9037
CYP450 2C19 inhibitorNon-inhibitor0.9025
CYP450 3A4 inhibitorNon-inhibitor0.8122
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7371
Ames testNon AMES toxic0.7738
CarcinogenicityNon-carcinogens0.8493
BiodegradationNot ready biodegradable0.8013
Rat acute toxicity2.5166 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.7132
hERG inhibition (predictor II)Inhibitor0.7974
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Eli lilly and co
Packagers
Dosage forms
FormRouteStrength
Capsuleoral10 mg/1
Capsuleoral10 mg
Capsuleoral100 mg
Capsuleoral100 mg/1
Capsuleoral18 mg/1
Capsuleoral18 mg
Capsuleoral25 mg
Capsuleoral25 mg/1
Capsuleoral40 mg/1
Capsuleoral40 mg
Capsuleoral60 mg
Capsuleoral60 mg/1
Capsuleoral80 mg
Capsuleoral80 mg/1
Kitoral
Prices
Unit descriptionCostUnit
Strattera 80 mg capsule6.94USD capsule
Strattera 100 mg capsule6.83USD capsule
Strattera 40 mg capsule6.43USD capsule
Strattera 60 mg capsule6.43USD capsule
Strattera 18 mg capsule6.03USD capsule
Strattera 25 mg capsule5.85USD capsule
Strattera 10 mg capsule5.84USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2209735 No2002-10-012016-01-04Canada
US5658590 Yes1997-05-262017-05-26Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubility27.8 mg/mLNot Available
logP3.9Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0039 mg/mLALOGPS
logP3.95ALOGPS
logP3.81ChemAxon
logS-4.8ALOGPS
pKa (Strongest Basic)9.8ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area21.26 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity79.44 m3·mol-1ChemAxon
Polarizability29.79 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Judith Aronhime, Stefano Bianchi, Eugenio Castelli, Paola Daverio, Silvia Mantovani, Adrienne Kovacsne-Mezei, “Processes for the preparation of atomoxetine hydrochloride.” U.S. Patent US20060211772, issued September 21, 2006.

US20060211772
General References
  1. Spencer TJ, Faraone SV, Michelson D, Adler LA, Reimherr FW, Glatt SJ, Biederman J: Atomoxetine and adult attention-deficit/hyperactivity disorder: the effects of comorbidity. J Clin Psychiatry. 2006 Mar;67(3):415-20. [PubMed:16649828 ]
  2. Pilhatsch MK, Burghardt R, Wandinger KP, Bauer M, Adli M: Augmentation with atomoxetine in treatment-resistant depression with psychotic features. A case report. Pharmacopsychiatry. 2006 Mar;39(2):79-80. [PubMed:16555170 ]
  3. Carpenter LL, Milosavljevic N, Schecter JM, Tyrka AR, Price LH: Augmentation with open-label atomoxetine for partial or nonresponse to antidepressants. J Clin Psychiatry. 2005 Oct;66(10):1234-8. [PubMed:16259536 ]
  4. Kratochvil CJ, Newcorn JH, Arnold LE, Duesenberg D, Emslie GJ, Quintana H, Sarkis EH, Wagner KD, Gao H, Michelson D, Biederman J: Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. J Am Acad Child Adolesc Psychiatry. 2005 Sep;44(9):915-24. [PubMed:16113620 ]
  5. McElroy SL, Guerdjikova A, Kotwal R, Welge JA, Nelson EB, Lake KA, Keck PE Jr, Hudson JI: Atomoxetine in the treatment of binge-eating disorder: a randomized placebo-controlled trial. J Clin Psychiatry. 2007 Mar;68(3):390-8. [PubMed:17388708 ]
  6. Purper-Ouakil D, Fourneret P, Wohl M, Reneric JP: [Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents]. Encephale. 2005 May-Jun;31(3):337-48. [PubMed:16142049 ]
  7. Simpson D, Plosker GL: Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder. Drugs. 2004;64(2):205-22. [PubMed:14717619 ]
  8. Montoya A, Hervas A, Cardo E, Artigas J, Mardomingo MJ, Alda JA, Gastaminza X, Garcia-Polavieja MJ, Gilaberte I, Escobar R: Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naive children and adolescents with attention deficit/hyperactivity disorder. Curr Med Res Opin. 2009 Nov;25(11):2745-54. doi: 10.1185/03007990903316152. [PubMed:19785510 ]
  9. Gaillez C, Sorbara F, Perrin E: [Atomoxetine (Strattera), an alternative in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children]. Encephale. 2007 Sep;33(4 Pt 1):621-8. [PubMed:18033153 ]
External Links
ATC CodesN06BA09
AHFS Codes
  • 28:92.00
PDB EntriesNot Available
FDA labelDownload (72.8 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AbirateroneThe serum concentration of Atomoxetine can be increased when it is combined with Abiraterone.
AcebutololAtomoxetine may increase the hypertensive activities of Acebutolol.
AminophyllineAtomoxetine may increase the hypertensive activities of Aminophylline.
AmphetamineAtomoxetine may increase the hypertensive activities of Amphetamine.
ArformoterolAtomoxetine may increase the tachycardic activities of Arformoterol.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Atomoxetine.
ArmodafinilAtomoxetine may increase the hypertensive activities of Armodafinil.
BenzphetamineAtomoxetine may increase the hypertensive activities of Benzphetamine.
BupropionThe serum concentration of Atomoxetine can be increased when it is combined with Bupropion.
CaffeineAtomoxetine may increase the hypertensive activities of Caffeine.
ChlorphentermineAtomoxetine may increase the hypertensive activities of Chlorphentermine.
CinacalcetThe serum concentration of Atomoxetine can be increased when it is combined with Cinacalcet.
CitalopramAtomoxetine may increase the QTc-prolonging activities of Citalopram.
ClenbuterolAtomoxetine may increase the hypertensive activities of Clenbuterol.
CobicistatThe serum concentration of Atomoxetine can be increased when it is combined with Cobicistat.
CocaineThe serum concentration of Atomoxetine can be increased when it is combined with Cocaine.
DarunavirThe serum concentration of Atomoxetine can be increased when it is combined with Darunavir.
DelavirdineThe serum concentration of Atomoxetine can be increased when it is combined with Delavirdine.
DexmethylphenidateAtomoxetine may increase the hypertensive activities of Dexmethylphenidate.
DextroamphetamineAtomoxetine may increase the hypertensive activities of Dextroamphetamine.
DiethylpropionAtomoxetine may increase the hypertensive activities of Diethylpropion.
DipivefrinAtomoxetine may increase the hypertensive activities of Dipivefrin.
DobutamineAtomoxetine may increase the hypertensive activities of Dobutamine.
DofetilideAtomoxetine may increase the QTc-prolonging activities of Dofetilide.
DopamineAtomoxetine may increase the hypertensive activities of Dopamine.
DoxapramAtomoxetine may increase the hypertensive activities of Doxapram.
DyphyllineAtomoxetine may increase the hypertensive activities of Dyphylline.
EphedrineAtomoxetine may increase the hypertensive activities of Ephedrine.
EpinephrineAtomoxetine may increase the hypertensive activities of Epinephrine.
FenoterolAtomoxetine may increase the hypertensive activities of Fenoterol.
FluoxetineThe serum concentration of Atomoxetine can be increased when it is combined with Fluoxetine.
FormoterolAtomoxetine may increase the tachycardic activities of Formoterol.
GoserelinAtomoxetine may increase the QTc-prolonging activities of Goserelin.
IndacaterolAtomoxetine may increase the tachycardic activities of Indacaterol.
IobenguaneThe therapeutic efficacy of Iobenguane can be decreased when used in combination with Atomoxetine.
IsocarboxazidIsocarboxazid may increase the central neurotoxic activities of Atomoxetine.
IsoprenalineAtomoxetine may increase the hypertensive activities of Isoprenaline.
LabetalolAtomoxetine may increase the hypertensive activities of Labetalol.
LeuprolideAtomoxetine may increase the QTc-prolonging activities of Leuprolide.
LinezolidLinezolid may increase the central neurotoxic activities of Atomoxetine.
LisdexamfetamineAtomoxetine may increase the hypertensive activities of Lisdexamfetamine.
MephentermineAtomoxetine may increase the hypertensive activities of Mephentermine.
MetaraminolAtomoxetine may increase the hypertensive activities of Metaraminol.
MethamphetamineAtomoxetine may increase the hypertensive activities of Methamphetamine.
MethotrimeprazineThe serum concentration of Atomoxetine can be increased when it is combined with Methotrimeprazine.
MethoxamineAtomoxetine may increase the hypertensive activities of Methoxamine.
MethylphenidateAtomoxetine may increase the hypertensive activities of Methylphenidate.
MidodrineAtomoxetine may increase the hypertensive activities of Midodrine.
MifepristoneMifepristone may increase the QTc-prolonging activities of Atomoxetine.
MoclobemideMoclobemide may increase the central neurotoxic activities of Atomoxetine.
ModafinilAtomoxetine may increase the hypertensive activities of Modafinil.
NaphazolineAtomoxetine may increase the hypertensive activities of Naphazoline.
NorepinephrineAtomoxetine may increase the hypertensive activities of Norepinephrine.
OlodaterolAtomoxetine may increase the tachycardic activities of Olodaterol.
OrciprenalineAtomoxetine may increase the hypertensive activities of Orciprenaline.
OxymetazolineAtomoxetine may increase the hypertensive activities of Oxymetazoline.
PanobinostatThe serum concentration of Atomoxetine can be increased when it is combined with Panobinostat.
ParoxetineThe serum concentration of Atomoxetine can be increased when it is combined with Paroxetine.
Peginterferon alfa-2bThe serum concentration of Atomoxetine can be decreased when it is combined with Peginterferon alfa-2b.
PhendimetrazineAtomoxetine may increase the hypertensive activities of Phendimetrazine.
PhenelzinePhenelzine may increase the central neurotoxic activities of Atomoxetine.
PhenmetrazineAtomoxetine may increase the hypertensive activities of Phenmetrazine.
PhentermineAtomoxetine may increase the hypertensive activities of Phentermine.
PhenylephrineAtomoxetine may increase the hypertensive activities of Phenylephrine.
PhenylpropanolamineAtomoxetine may increase the hypertensive activities of Phenylpropanolamine.
PirbuterolAtomoxetine may increase the tachycardic activities of Pirbuterol.
ProcarbazineProcarbazine may increase the central neurotoxic activities of Atomoxetine.
PropylhexedrineAtomoxetine may increase the hypertensive activities of Propylhexedrine.
PseudoephedrineAtomoxetine may increase the hypertensive activities of Pseudoephedrine.
QuinidineThe serum concentration of Atomoxetine can be increased when it is combined with Quinidine.
RacepinephrineAtomoxetine may increase the hypertensive activities of Racepinephrine.
RasagilineRasagiline may increase the central neurotoxic activities of Atomoxetine.
RitodrineAtomoxetine may increase the hypertensive activities of Ritodrine.
RitonavirThe serum concentration of Atomoxetine can be increased when it is combined with Ritonavir.
SalbutamolAtomoxetine may increase the tachycardic activities of Salbutamol.
SalmeterolAtomoxetine may increase the tachycardic activities of Salmeterol.
SelegilineSelegiline may increase the central neurotoxic activities of Atomoxetine.
StiripentolThe serum concentration of Atomoxetine can be increased when it is combined with Stiripentol.
Tedizolid PhosphateTedizolid Phosphate may increase the central neurotoxic activities of Atomoxetine.
TerbinafineThe serum concentration of Atomoxetine can be increased when it is combined with Terbinafine.
TerbutalineAtomoxetine may increase the tachycardic activities of Terbutaline.
TheophyllineAtomoxetine may increase the hypertensive activities of Theophylline.
ThioridazineThe serum concentration of Atomoxetine can be increased when it is combined with Thioridazine.
TiclopidineThe metabolism of Atomoxetine can be decreased when combined with Ticlopidine.
TipranavirThe serum concentration of Atomoxetine can be increased when it is combined with Tipranavir.
TranylcypromineTranylcypromine may increase the central neurotoxic activities of Atomoxetine.
TriprolidineAtomoxetine may increase the hypertensive activities of Triprolidine.
Food Interactions
  • In the presence of food, the absorption rate is reduced, without the quantity absorbed being affected.
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
General Function:
Norepinephrine:sodium symporter activity
Specific Function:
Amine transporter. Terminates the action of noradrenaline by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A2
Uniprot ID:
P23975
Molecular Weight:
69331.42 Da
References
  1. Biederman J, Heiligenstein JH, Faries DE, Galil N, Dittmann R, Emslie GJ, Kratochvil CJ, Laws HF, Schuh KJ: Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit/hyperactivity disorder. Pediatrics. 2002 Dec;110(6):e75. [PubMed:12456942 ]
  2. Spencer T, Heiligenstein JH, Biederman J, Faries DE, Kratochvil CJ, Conners CK, Potter WZ: Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002 Dec;63(12):1140-7. [PubMed:12523874 ]
  3. Michelson D, Adler L, Spencer T, Reimherr FW, West SA, Allen AJ, Kelsey D, Wernicke J, Dietrich A, Milton D: Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry. 2003 Jan 15;53(2):112-20. [PubMed:12547466 ]
  4. Wernicke JF, Faries D, Girod D, Brown J, Gao H, Kelsey D, Quintana H, Lipetz R, Michelson D, Heiligenstein J: Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf. 2003;26(10):729-40. [PubMed:12862507 ]
  5. Wernicke JF, Adler L, Spencer T, West SA, Allen AJ, Heiligenstein J, Milton D, Ruff D, Brown WJ, Kelsey D, Michelson D: Changes in symptoms and adverse events after discontinuation of atomoxetine in children and adults with attention deficit/hyperactivity disorder: a prospective, placebo-controlled assessment. J Clin Psychopharmacol. 2004 Feb;24(1):30-5. [PubMed:14709944 ]
  6. Garnock-Jones KP, Keating GM: Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. [PubMed:19445548 ]
  7. Kaplan S, Heiligenstein J, West S, Busner J, Harder D, Dittmann R, Casat C, Wernicke JF: Efficacy and safety of atomoxetine in childhood attention-deficit/hyperactivity disorder with comorbid oppositional defiant disorder. J Atten Disord. 2004 Oct;8(2):45-52. [PubMed:15801334 ]
  8. Purper-Ouakil D, Fourneret P, Wohl M, Reneric JP: [Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents]. Encephale. 2005 May-Jun;31(3):337-48. [PubMed:16142049 ]
  9. Gaillez C, Sorbara F, Perrin E: [Atomoxetine (Strattera), an alternative in the treatment of attention-deficit/hyperactivity disorder (ADHD) in children]. Encephale. 2007 Sep;33(4 Pt 1):621-8. [PubMed:18033153 ]
  10. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Serotonin:sodium symporter activity
Specific Function:
Serotonin transporter whose primary function in the central nervous system involves the regulation of serotonergic signaling via transport of serotonin molecules from the synaptic cleft back into the pre-synaptic terminal for re-utilization. Plays a key role in mediating regulation of the availability of serotonin to other receptors of serotonergic systems. Terminates the action of serotonin an...
Gene Name:
SLC6A4
Uniprot ID:
P31645
Molecular Weight:
70324.165 Da
References
  1. Tatsumi M, Groshan K, Blakely RD, Richelson E: Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol. 1997 Dec 11;340(2-3):249-58. [PubMed:9537821 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Monoamine transmembrane transporter activity
Specific Function:
Amine transporter. Terminates the action of dopamine by its high affinity sodium-dependent reuptake into presynaptic terminals.
Gene Name:
SLC6A3
Uniprot ID:
Q01959
Molecular Weight:
68494.255 Da
References
  1. Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW: Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology. 2002 Nov;27(5):699-711. [PubMed:12431845 ]
Kind
Protein group
Organism
Human
Pharmacological action
unknown
Actions
blocker
General Function:
Voltage-gated cation channel activity
Specific Function:
NMDA receptor subtype of glutamate-gated ion channels with high calcium permeability and voltage-dependent sensitivity to magnesium. Mediated by glycine. This protein plays a key role in synaptic plasticity, synaptogenesis, excitotoxicity, memory acquisition and learning. It mediates neuronal functions in glutamate neurotransmission. Is involved in the cell surface targeting of NMDA receptors (By similarity).
Components:
NameUniProt IDDetails
Glutamate receptor ionotropic, NMDA 1Q05586 Details
Glutamate receptor ionotropic, NMDA 2AQ12879 Details
Glutamate receptor ionotropic, NMDA 2BQ13224 Details
Glutamate receptor ionotropic, NMDA 2CQ14957 Details
Glutamate receptor ionotropic, NMDA 2DO15399 Details
Glutamate receptor ionotropic, NMDA 3AQ8TCU5 Details
Glutamate receptor ionotropic, NMDA 3BO60391 Details
References
  1. Ludolph AG, Udvardi PT, Schaz U, Henes C, Adolph O, Weigt HU, Fegert JM, Boeckers TM, Fohr KJ: Atomoxetine acts as an NMDA receptor blocker in clinically relevant concentrations. Br J Pharmacol. 2010 May;160(2):283-91. doi: 10.1111/j.1476-5381.2010.00707.x. [PubMed:20423340 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Purper-Ouakil D, Fourneret P, Wohl M, Reneric JP: [Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents]. Encephale. 2005 May-Jun;31(3):337-48. [PubMed:16142049 ]
  2. Garnock-Jones KP, Keating GM: Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs. 2009;11(3):203-26. doi: 10.2165/00148581-200911030-00005. [PubMed:19445548 ]
  3. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on July 01, 2016 03:05